Sarcoma & GIST
Two new fusion partners for the USP6 gene were found using AMP-based targeted next-generation sequencing.
The statistical significance of the improvements varied depending on how progression-free survival was measured.
From the Journals
Analysis of the sequence context surrounding chromoplexy breaks may provide clues and potentially point to a therapeutic vulnerability that could...
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration,...
Chemotherapy halved the risk of disease progression and death for patients with low probability of 10-year overall survival.
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
CHICAGO – Of 80 patients with previously untreated metastatic soft-tissue sarcomas, 2 had complete, durable responses to oral trofosfamide.
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.